Table 1. Characteristics and the titer of anti-SRBD SARS-CoV-2 antibody between vaccinated and naturally SARS-CoV-2 infected individuals (n=118).
| Variable | Natural infection n (%), (n=58) | COVID-19 vaccination n (%), (n=60) |
|---|---|---|
| Age, median (IQR), year | 53.52 (18.01–78.09) | 44.06 (19.00–62.09) |
| Age group, year | ||
| 18-40 | 11 (18.9) | 26 (43.3) |
| >40–60 | 31 (52.4) | 31 (51.7) |
| >60 | 16 (27.6) | 3 (5.0) |
| Gender | ||
| Male | 20 (34.4) | 25 (41.7) |
| Female | 38 (65.5) | 35 (58.3) |
| Anti-SRBD antibody, mean (±SD), IU/mL | 188.47±94.57 | 63.62±82.57 |
| Antibody titer group, IU/mL | ||
| 0–50 | 12 (20.6) | 38 (63.3) |
| 51–100 | 2 (3.4) | 9 (15.0) |
| 101–200 | 5 (8.6) | 6 (10.0) |
| >200 | 39 (67.2) | 7 (11.7) |
| Antibody titer group | ||
| Protective | 52 (89.7) | 36 (60.0) |
| Non-protective | 6 (10.3) | 24 (40.0) |
The maximum detectable antibody titer was 250 IU/mL.